Multi-institutional observational study of dermatologic events sssociated with enfortumab vedotin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050230125

Enrollment

300

Registered

2023-11-09

Start date

2023-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelila carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable or metastatic urothelial carcinoma who received enfortumab vedotin between January 1, 2020 and May 31, 2023 at the Department of Urology, Kyoto University Hospital and at participating institutions in the multicenter study.

Exclusion criteria

Exclusion criteria: Not available

Design outcomes

Primary

Measure	Time frame
Details of dermatological evens after enfortumab vedotin administration (frequency, timing, location)	—

Contacts

Public ContactYUKI KITA

Kyoto University Hospital

kitayuki@kuhp.kyoto-u.ac.jp+81-75-751-3337

Outcome results